Serum FGF-21 and FGF-23 in association with gestational diabetes: a longitudinal case-control study

References

[1] American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2017;40:S11–24.10.2337/dc17-S005Search in Google Scholar PubMed

[2] Ta S. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37:S81.10.2337/dc14-S081Search in Google Scholar PubMed

[3] Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care. 2012;35:780–6.10.2337/dc11-1790Search in Google Scholar PubMed PubMed Central

[4] Damm P, Houshmand-Oeregaard A, Kelstrup L, Lauenborg J, Mathiesen ER, Clausen TD. Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark. Diabetologia. 2016;59:1396–9.10.1007/s00125-016-3985-5Search in Google Scholar PubMed

[5] Itoh N, Ohta H, Konishi M. Endocrine FGFs: evolution, physiology, pathophysiology, and pharmacotherapy. Front Endocrinol. 2015;6:154.10.3389/fendo.2015.00154Search in Google Scholar PubMed PubMed Central

[6] Itoh N, Ohta H. Roles of FGFs as adipokines in adipose tissue development, remodeling, and metabolism. Front Endocrinol. 2014;5:18.10.3389/fendo.2014.00018Search in Google Scholar

[7] Itoh N. FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases. Front Endocrinol. 2014;5:107.10.3389/fendo.2014.00107Search in Google Scholar PubMed PubMed Central

[8] Murata Y, Konishi M, Itoh N. FGF21 as an endocrine regulator in lipid metabolism: from molecular evolution to physiology and pathophysiology. J Nutr Metab. 2011;2011.10.1155/2011/981315Search in Google Scholar PubMed PubMed Central

[9] Stein S, Stepan H, Kratzsch J, Verlohren M, Verlohren H-J, Drynda K, et al. Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metab Clin Exp. 2010;59:33–7.10.1016/j.metabol.2009.07.003Search in Google Scholar PubMed

[10] Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91–104.10.1146/annurev.med.051308.111339Search in Google Scholar PubMed PubMed Central

[11] Kanbay M, Vervloet M, Cozzolino M, Siriopol D, Covic A, Goldsmith D, et al. Novel faces of fibroblast growth factor 23 (FGF23): iron deficiency, inflammation, insulin resistance, left ventricular hypertrophy, proteinuria and acute kidney injury. Calcif Tissue Int. 2017;100:217–28.10.1007/s00223-016-0206-7Search in Google Scholar PubMed

[12] Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol. 2009;9:805–810.10.1016/j.coph.2009.07.001Search in Google Scholar PubMed

[13] Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutiérrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One. 2015;10:e0122885.10.1371/journal.pone.0122885Search in Google Scholar PubMed PubMed Central

[14] Wojcik M, Dolezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, Starzyk JB. FGF23 contributes to insulin sensitivity in obese adolescents – preliminary results. Clin Endocrinol (Oxf). 2012;77:537–40.10.1111/j.1365-2265.2011.04299.xSearch in Google Scholar PubMed

[15] Wojcik M, Janus D, Dolezal-Oltarzewska K, Drozdz D, Sztefko K, Starzyk JB. The association of FGF23 levels in obese adolescents with insulin sensitivity. J Pediatr Endocrinol Metab. 2012;25:687–90.10.1515/jpem-2012-0064Search in Google Scholar PubMed

[16] Garland JS, Holden RM, Ross R, Adams MA, Nolan RL, Hopman WM, et al. Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3–5 chronic kidney disease patients. J Diabetes Complications. 2014;28:61–5.10.1016/j.jdiacomp.2013.09.004Search in Google Scholar PubMed

[17] Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600–8.10.1681/ASN.2006080936Search in Google Scholar PubMed

[18] Bär L, Feger M, Fajol A, Klotz L-O, Zeng S, Lang F, et al. Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc Natl Acad Sci USA. 2018;115:5804–9.10.1073/pnas.1800160115Search in Google Scholar PubMed PubMed Central

[19] Burlina S, Dalfrà MG, Chilelli NC, Lapolla A. Gestational diabetes mellitus and future cardiovascular risk: an update. Int J Endocrinol. 2016;2016.10.1155/2016/2070926Search in Google Scholar PubMed PubMed Central

[20] Kizilgul M, Kan S, Beysel S, Apaydin M, Ozcelik O, Caliskan M, et al. Is fibroblast growth factor 23 a new cardiovascular risk marker in gestational diabetes? Arch Endocrinol Metab. 2017:562-6.10.1590/2359-3997000000287Search in Google Scholar PubMed

[21] Tuzun D, Oguz A, Aydin MN, Kurutas EB, Ercan O, Sahin M, et al. Is FGF-23 an early indicator of atherosclerosis and cardiac dysfunction in patients with gestational diabetes? Arch Endocrinol Metab. 2018;62:506–13.10.20945/2359-3997000000070Search in Google Scholar PubMed

[22] Mosavat M, Omar SZ, Tan PC, Razif MFM, Sthaneshwar P. Leptin and soluble leptin receptor in association with gestational diabetes: a prospective case–control study. Arch Gynecol Obstet. 2017;297:797–803.10.1007/s00404-017-4617-0Search in Google Scholar PubMed

[23] American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29:s43–8.10.2337/diacare.29.s1.06.s43Search in Google Scholar

[24] Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, Araki-Sasaki R, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001;24:362–5.10.2337/diacare.24.2.362Search in Google Scholar PubMed

[25] Tam CHT, Ho JSK, Wang Y, Lee HM, Lam VKL, Germer S, et al. Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta-cell function in Chinese subjects. PLoS ONE. 2010;5:e11428.10.1371/journal.pone.0011428Search in Google Scholar PubMed PubMed Central

[26] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.10.1007/BF00280883Search in Google Scholar PubMed

[27] Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.10.1210/jcem.85.7.6661Search in Google Scholar PubMed

[28] Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112:683–92.10.1172/JCI18399Search in Google Scholar PubMed PubMed Central

[29] Majumdar V, Christopher R. Association of exonic variants of Klotho with metabolic syndrome in Asian Indians. Clin Chim Acta. 2011;412:1116–21.10.1016/j.cca.2011.02.034Search in Google Scholar PubMed

[30] Lorenzi O, Veyrat-Durebex C, Wollheim CB, Villemin P, Rohner-Jeanrenaud F, Zanchi A, et al. Evidence against a direct role of klotho in insulin resistance. Pflüg Arch Eur J Physiol. 2010;459:465–73.10.1007/s00424-009-0735-2Search in Google Scholar PubMed

[31] Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627–35.10.1172/JCI23606Search in Google Scholar PubMed PubMed Central

[32] Kharitonenkov A, Shanafelt AB. FGF21: a novel prospect for the treatment of metabolic diseases. Curr Opin Investig Drugs. 2009;10:359–64.Search in Google Scholar

[33] Iliodromiti S, Sassarini J, Kelsey TW, Lindsay RS, Sattar N, Nelson SM. Accuracy of circulating adiponectin for predicting gestational diabetes: a systematic review and meta-analysis. Diabetologia. 2016;59:692–9.10.1007/s00125-015-3855-6Search in Google Scholar PubMed PubMed Central

[34] Vaidya A, Williams JS, Forman JP. The independent association between 25-hydroxyvitamin D and adiponectin and its relation with bmi in two large cohorts: the NHS and the HPFS. Obesity. 2012;20:186–91.10.1038/oby.2011.210Search in Google Scholar PubMed PubMed Central

[35] Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutiérrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS ONE. 2015;10:e0122885.10.1371/journal.pone.0122885Search in Google Scholar PubMed PubMed Central

[36] Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205:385–90.10.1016/j.atherosclerosis.2009.01.001Search in Google Scholar PubMed

[37] Sit D, Tanrıverdi E, Kayabasi H, Erdem M, Sari H. Is FGF23 effective on insulin resistance in individuals with metabolic syndrome? Horm Mol Biol Clin Investig. 2018;35, DOI: 10.1515/hmbci-2018-0018.10.1515/hmbci-2018-0018Search in Google Scholar PubMed

[38] Miranda J, Romero R, Korzeniewski SJ, Schwartz AG, Chaemsaithong P, Stampalija T, et al. The anti-aging factor α-klotho during human pregnancy and its expression in pregnancies complicated by small-for-gestational-age neonates and/or preeclampsia. J Matern Fetal Neonatal Med. 2014;27:449–57.10.3109/14767058.2013.818652Search in Google Scholar PubMed PubMed Central

[39] Salles JP. Bone metabolism during pregnancy. In: Proceedings of the Annales d’endocrinologie, vol. 77. Elsevier; 2016:163–8.10.1016/j.ando.2016.04.004Search in Google Scholar PubMed

[40] Kirby BJ, Ma Y, Martin HM, Buckle Favaro KL, Karaplis AC, Kovacs CS. Upregulation of calcitriol during pregnancy and skeletal recovery after lactation do not require parathyroid hormone. J Bone Miner Res. 2013;28:1987–2000.10.1002/jbmr.1925Search in Google Scholar PubMed

[41] Kovacs CS, Kronenberg HM. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr Rev. 1997;18:832–72.10.1210/edrv.18.6.0319Search in Google Scholar PubMed

[42] Ge X, Wang Y, Lam KS, Xu A. Metabolic actions of FGF21: molecular mechanisms and therapeutic implications. Acta Pharm Sin B. 2012;2:350–7.10.1016/j.apsb.2012.06.011Search in Google Scholar

[43] Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou Z-G, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57:1246–53.10.2337/db07-1476Search in Google Scholar PubMed

[44] Asrih M, Veyrat-Durebex C, Poher A-L, Lyautey J, Rohner-Jeanrenaud F, Jornayvaz FR. Leptin as a potential regulator of FGF21. Cell Physiol Biochem. 2016;38:1218–25.10.1159/000443070Search in Google Scholar PubMed